|

Ramantamig Clinical Trials

1 actively recruiting trial across 1 location

Also known as: BCMAxGPRC5DxCD3

Pipeline

Phase 2: 1

Top Sponsors

  • Janssen Research & Development, LLC1

Indications

  • Relapse Multiple Myeloma1
  • Refractory Multiple Myeloma1
  • Multiple Myeloma1
  • Cancer1

San Francisco, California1 trial

A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events

University of California San Francisco

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.